Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

ABSTRACT Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH). A population pharmacokinetic (PK)/pharmacodynamic (PD...

Cijeli opis

Bibliografski detalji

Glavni autori:	Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2025-11-01
Serija:	CPT: Pharmacometrics & Systems Pharmacology
Teme:	evinacumab exposure‐response homozygous familial hypercholesterolemia pediatrics pharmacokinetics
Online pristup:	https://doi.org/10.1002/psp4.70016
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!